6-Alkyl Naphthamide Compounds for Ocular Hypertension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary and secondary forms, face challenges in effectively reducing intraocular pressure due to obstruction of aqueous humor outflow, with existing ocular hypotensive agents having limitations in efficacy and comfort for patients.
Innovation Solution
Development of well-defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds, which can be administered topically as ophthalmically acceptable pharmaceutical compositions to treat glaucoma and ocular hypertension, facilitating the reduction of intraocular pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ocular hypotensive agents are used to treat glaucoma, then intraocular pressure reduction is achieved, but patient comfort and efficacy are limited
Solution Approach 1:
The patent modifies the chemical structure of naphthamide and quinoline compounds by changing parameters such as adding alkyl groups at specific positions (6-alkyl or hydroxyalkyl), adjusting molecular weight, and modifying functional groups. These parameter changes optimize the compounds for both efficacy in reducing intraocular pressure and improved patient comfort, resolving the contradiction between therapeutic reliability and ease of operation.
2Stress or pressure
If aqueous humor outflow is obstructed, then glaucoma condition develops, but current drugs fail to effectively reduce pressure
Solution Approach 1:
The patent extracts and targets specific molecular interactions responsible for aqueous humor outflow obstruction. By designing compounds that specifically interfere with the obstruction mechanism at the cellular or molecular level (rather than using general pressure-reducing agents), the invention achieves more reliable and effective intraocular pressure reduction, directly addressing the root cause of the glaucoma condition.
Data Source
AI summary
This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension.